-$0.30 Earnings Per Share Expected for GlycoMimetics Inc (GLYC) This Quarter
Analysts forecast that GlycoMimetics Inc (NASDAQ:GLYC) will report earnings of ($0.30) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for GlycoMimetics’ earnings, with estimates ranging from ($0.34) to ($0.27). GlycoMimetics posted earnings of ($0.24) per share in the same quarter last year, which would suggest a negative year over year growth rate of 25%. The business is scheduled to issue its next earnings report on Wednesday, November 14th.
On average, analysts expect that GlycoMimetics will report full-year earnings of ($1.24) per share for the current financial year, with EPS estimates ranging from ($1.33) to ($1.13). For the next fiscal year, analysts forecast that the business will report earnings of ($1.14) per share, with EPS estimates ranging from ($1.85) to ($0.09). Zacks’ EPS calculations are a mean average based on a survey of research firms that follow GlycoMimetics.
GlycoMimetics (NASDAQ:GLYC) last released its earnings results on Friday, August 10th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.08.
A number of large investors have recently bought and sold shares of the business. California Public Employees Retirement System bought a new stake in shares of GlycoMimetics during the 1st quarter valued at $166,000. Metropolitan Life Insurance Co. NY bought a new stake in shares of GlycoMimetics during the 2nd quarter valued at $189,000. Voya Investment Management LLC bought a new stake in shares of GlycoMimetics during the 2nd quarter valued at $205,000. DekaBank Deutsche Girozentrale bought a new stake in shares of GlycoMimetics during the 1st quarter valued at $220,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of GlycoMimetics during the 2nd quarter valued at $264,000.
Shares of GLYC stock traded up $0.12 during trading hours on Friday, hitting $14.35. 3,391 shares of the company’s stock traded hands, compared to its average volume of 261,049. GlycoMimetics has a 12-month low of $10.25 and a 12-month high of $26.05. The firm has a market capitalization of $608.83 million, a price-to-earnings ratio of -12.65 and a beta of 3.23.
GlycoMimetics, Inc, a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma.
Further Reading: Do Tariffs Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.